The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
The Commonwealth Fund 2024 Biennial Health Insurance Survey found that 8 percent of Americans had no health insurance in 2023. It also found that 3 in 5 underinsured adults said they avoided care ...
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
The firm backed the insurance broker's creation in 2011, sold a majority stake in 2015 and reacquired it in 2019. Mao Geping Cosmetics shares jumped in their trading debut in Hong Kong after an ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
They are currently approved for treating diabetes, obesity and those with a history of cardiovascular disease in people who ...
Weight-loss drugs like Ozempic seem like a miracle. But they've also created a gold rush for online scammers and hucksters.
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...
Weight-loss drugs like Ozempic seem like a miracle. But they've also created a gold rush for online scammers and hucksters.
The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...